公开(公告)号：EP3010520A1

公开(公告)日：2016-04-27

申请号：EP14736568.8

申请日：2014-06-16

申请人： Access Business Group International LLC ,  The Regents of the University of Colorado, a body corporate

发明人： RANA, Jatinder ,  RANDOLPH, Russell, Keith ,  SCHOLTEN, Jeffrey ,  LE, Myphuong, Thi ,  JOHNSON, Richard, J. ,  LANASPA GARCIA, Miguel, Angel

IPC分类号： A61K36/75 ,  A61K36/12 ,  A61K36/185 ,  A61K36/19 ,  A61K36/23 ,  A61K36/232 ,  A61K36/38 ,  A61K36/44 ,  A61K36/487 ,  A61K36/539 ,  A61K36/605 ,  A61K36/62 ,  A61K36/73 ,  A61P3/04 ,  A61P3/10

CPC分类号： A61K36/73 ,  A61K36/12 ,  A61K36/185 ,  A61K36/19 ,  A61K36/23 ,  A61K36/232 ,  A61K36/38 ,  A61K36/44 ,  A61K36/487 ,  A61K36/539 ,  A61K36/605 ,  A61K36/62 ,  A61K36/75

摘要： A composition for inhibiting ketohexokinase, for example, ketohexokinase-C (KHK-C) activity, may include a plant extract exhibiting at least IC50 (i.e., 50% KHK-C inhibition at a concentration in the range of from about 0.1 μg/mL to about 1000 μg/mL. The composition may be in a form suitable for oral ingestion. A method for inhibiting KHK-C activity in a subject may include administering a plant extract that exhibits at least 50% KHK-C inhibition at a concentration from about 0.1 μg/mL to about 1000 μg/mL. The administering may be done to treat or prevent at least one of sugar addiction, obesity, or metabolic syndrome. The administering may be done to provide a diminished craving in the subject from at least one member selected from the group consisting of craving of sugar, fructose, fructose-containing sugars, carbohydrates, and combinations thereof. The subject may be pre-diabetic, diabetic and or insulin resistant.

公开(公告)号：EP2600897A2

公开(公告)日：2013-06-12

申请号：EP11815418.6

申请日：2011-08-08

申请人： The Regents of the University of Colorado, A Body Corporate

发明人： JOHNSON, Richard, J. ,  LANASPA, Miguel, A. ,  ISHIMOTO, Takuji

IPC分类号： A61K39/395 ,  A61K48/00 ,  A61K31/7105 ,  A61K31/70 ,  A61P3/10 ,  A61P3/04 ,  A61P3/00

CPC分类号： A61K39/3955 ,  A61K31/415 ,  A61K31/427 ,  A61K31/7052 ,  A61K38/005 ,  A61K39/39533 ,  A61K45/06 ,  C07K16/40 ,  C12N9/1205 ,  C12N15/1137 ,  A61K2300/00

摘要： The invention relates to the use of isoform-specific fructokinase (ketohexokinase) (KHK) inhibitors alone or in combination with various agents to both prevent and treat a wide variety of diseases including, but not limited to, sugar craving, obesity, features of metabolic syndrome (including insulin resistance, hypertriglyceridemia, hypertension, and fatty liver), polyuria, proximal tubular injury, and diabetic kidney disease.